The authors presented the complex relationship between iNOS, the immune response and tumor progression, indicating that there is no relationship between iNOS expression and the clinical stage of disease (FIGO), histological grade, response to chemotherapy, and disease-free survival ≤ 24 months. Here, NOS2 is linked to neoplasm.